They are now one of the largest disease-focused venture philanthropy funds in the world, with $100m in assets and our philanthropic dollars are spurring private investment to ultimately secure the billions we need to generate cures.

The portfolio consists of therapeutics, diagnostics, devices and vaccines, with an emphasis on cure-oriented therapies.

The fund leverages philanthropic capital to build a portfolio of investments that are both attractive to financially motivated investors and are compelling to the T1D community. Yet, it is risky to invest in a fund fully concentrated in one disease.

We need more philanthropists to disrupt and de-risk the investment market in T1D to continue the investment track record and ultimately create a perpetual source of financing and T1D strategic expertise that will be essential as T1D therapies mature.

The aim for T1D Fund portfolio companies is to achieve success, not only to deliver life-changing solutions for individuals living with or at risk of T1D today, but to also create a pipeline of next-generation novel opportunities tomorrow. As a high-impact philanthropic vehicle, all returns on the Fund’s investments are recycled back into the T1D mission.